Form 4: Altimmune CSO Granted Significant Equity Awards

Altimmune's Chief Scientific Officer, M Scot Roberts, was granted 222,670 stock options and 95,430 restricted stock units.

Summary

• M Scot Roberts, Chief Scientific Officer of Altimmune, Inc. (ALT), reported the acquisition of equity awards.
• The awards include 222,670 stock options with an exercise price of $4.46 per share.
• Also granted were 95,430 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The stock options vest over four years, with 25% vesting on February 26, 2027, and the remainder vesting in equal monthly installments for the subsequent 36 months.
• The RSUs also vest over four years, with 25% vesting on February 26, 2027, and the remainder vesting in equal annual installments for the subsequent three years.
• Vesting for both awards is subject to the reporting person's continued service through the applicable vesting dates.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, without indicating any immediate operational or financial performance changes.

Positives

• The granting of equity awards aligns the Chief Scientific Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The significant number of options and RSUs (totaling 318,100 potential shares) represents a substantial commitment to the executive and their role in the company's future.

Future Outlook

The vesting schedules for both stock options and restricted stock units extend over four years, indicating an expectation of continued service from the Chief Scientific Officer and a long-term incentive structure designed to align executive performance with company growth.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock options and restricted stock units, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives, aligning their performance with shareholder value creation and long-term strategic goals.

Comparison to Industry Standards

• Equity compensation packages for Chief Scientific Officers in the biotech sector typically include a mix of stock options and restricted stock units, similar to this grant.
• Companies like Moderna (MRNA) and BioNTech (BNTX) frequently utilize such structures to incentivize R&D leadership, with vesting schedules commonly ranging from three to five years to ensure long-term commitment to drug development pipelines.
• The specific grant size is commensurate with the executive's role and the company's stage of development, reflecting competitive compensation practices within the industry.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the Chief Scientific Officer's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: This grant reinforces the company's commitment to retaining key talent, which can positively impact employee morale and stability.

Next Steps

• Vesting of stock options and restricted stock units will occur according to the specified schedules, contingent on continued service.

Key Dates

Keywords

Altimmune, ALT, Form 4, insider transaction, stock options, restricted stock units, equity awards, M Scot Roberts, Chief Scientific Officer